NewAmsterdam Pharma Company N.V. Selling, General and Administrative Expense
NewAmsterdam Pharma Company N.V. (NAMS) reported Selling, General and Administrative Expense of $26.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. selling, general and administrative expense for the quarter ending 2026-06-30 was $26.89M, a 1.36% decline year-over-year.
- NewAmsterdam Pharma Company N.V. selling, general and administrative expense for the quarter ending 2026-03-31 was $23.45M, a 13.63% decline year-over-year.
- NewAmsterdam Pharma Company N.V. selling, general and administrative expense for the quarter ending 2025-12-31 was $27.42M, a 29.91% increase year-over-year.
- NewAmsterdam Pharma Company N.V. selling, general and administrative expense for the quarter ending 2025-09-30 was $24.52M, a 33.17% increase year-over-year.
- NewAmsterdam Pharma Company N.V. selling, general and administrative expense for fiscal 2025 was $106.35M, a 50.97% increase from fiscal 2024.
- NewAmsterdam Pharma Company N.V. selling, general and administrative expense for fiscal 2024 was $70.45M, a 87.19% increase from fiscal 2023.
- NewAmsterdam Pharma Company N.V. selling, general and administrative expense for fiscal 2023 was $37.63M, a 92.92% increase from fiscal 2022.
- NewAmsterdam Pharma Company N.V. selling, general and administrative expense for fiscal 2022 was $19.51M, a 224.95% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $26.89M 10-Q · filed 2026-08-05 | $50.34M 10-Q · filed 2026-08-05 | $77.76M derived: sum of 3 quarters · filed 2026-08-05 | $102.28M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $23.45M 10-Q · filed 2026-05-07 | $50.87M derived: sum of 2 quarters · filed 2026-05-07 | $75.39M derived: sum of 3 quarters · filed 2026-05-07 | $102.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $27.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $51.94M derived: sum of 2 quarters · filed 2026-02-18 | $79.20M derived: sum of 3 quarters · filed 2026-08-05 | $106.35M 10-K · filed 2026-02-18 |
| 2025-09-30 | $24.52M 10-Q · filed 2025-11-05 | $51.78M derived: sum of 2 quarters · filed 2026-08-05 | $78.94M 10-Q · filed 2025-11-05 | $100.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $27.26M 10-Q · filed 2026-08-05 | $54.42M 10-Q · filed 2026-08-05 | $75.52M derived: sum of 3 quarters · filed 2026-08-05 | $93.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $27.15M 10-Q · filed 2026-05-07 | $48.26M derived: sum of 2 quarters · filed 2026-05-07 | $66.67M derived: sum of 3 quarters · filed 2026-05-07 | $83.14M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $21.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $39.52M derived: sum of 2 quarters · filed 2026-02-18 | $55.99M derived: sum of 3 quarters · filed 2026-02-18 | $70.45M 10-K · filed 2026-02-18 |
| 2024-09-30 | $18.41M 10-Q · filed 2025-11-05 | $34.89M derived: sum of 2 quarters · filed 2025-11-05 | $49.34M 10-Q · filed 2025-11-05 | $59.92M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-30 | $16.48M 10-Q · filed 2025-08-06 | $30.93M 10-Q · filed 2025-08-06 | $41.51M derived: sum of 3 quarters · filed 2026-02-18 | $50.64M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-31 | $14.45M 10-Q · filed 2025-05-08 | $25.04M derived: sum of 2 quarters · filed 2026-02-18 | $34.17M derived: sum of 3 quarters · filed 2026-02-18 | $44.02M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-31 | $10.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $19.71M derived: sum of 2 quarters · filed 2026-02-18 | $29.57M derived: sum of 3 quarters · filed 2026-02-18 | $37.63M 10-K · filed 2026-02-18 |
| 2023-09-30 | $9.13M 10-Q · filed 2024-11-06 | $18.99M derived: sum of 2 quarters · filed 2024-11-06 | $27.05M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $9.86M 10-Q · filed 2024-08-07 | $17.92M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $8.06M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $19.51M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $6.00M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |